Compare Abrdn Physical Platinum Shares ETF (PPLT) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs 10X Genomics Inc — how do they compare? Abrdn Physical Platinum Shares ETF trades at $14.77, while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| PPLT | TXG | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $47.20 |
52-Week Low | $11.78 | $11.34 |
Market Cap | — | $5.48B |
Enterprise Value | — | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT trades at $14.47, down 0.21% on the day, with a strong bearish technical signal from moving averages and a neutral stance from oscillators. The stock underwent a 1:10 forward split effective May 18, 2026. Recent news highlights platinum's underperformance versus gold and silver, with some analysts viewing the gap as a potential catch-up opportunity, while others caution after a significant rally.
The outlook is mixed; technicals suggest near-term pressure, but the valuation gap in precious metals could present a long-term opportunity. Key risks include commodity price volatility and the ETF's lack of dividend income. Investor sentiment is divided between those betting on a rebound and those taking profits after strong gains.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
